Metsera (MTSR) Competitors $29.45 +0.59 (+2.04%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTSR vs. VTRS, QGEN, MRNA, ASND, BBIO, BPMC, VRNA, ROIV, ELAN, and RVMDShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Its Competitors Viatris Qiagen Moderna Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Viatris (NASDAQ:VTRS) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Does the media prefer VTRS or MTSR? In the previous week, Metsera had 1 more articles in the media than Viatris. MarketBeat recorded 1 mentions for Metsera and 0 mentions for Viatris. Metsera's average media sentiment score of 0.59 beat Viatris' score of 0.00 indicating that Metsera is being referred to more favorably in the news media. Company Overall Sentiment Viatris Neutral Metsera Positive Do analysts recommend VTRS or MTSR? Viatris currently has a consensus price target of $10.40, indicating a potential upside of 12.43%. Metsera has a consensus price target of $55.00, indicating a potential upside of 86.76%. Given Metsera's stronger consensus rating and higher probable upside, analysts clearly believe Metsera is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, VTRS or MTSR? Metsera has lower revenue, but higher earnings than Viatris. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.74-$634.20M-$3.17-2.92MetseraN/AN/A-$209.13MN/AN/A Is VTRS or MTSR more profitable? Metsera has a net margin of 0.00% compared to Viatris' net margin of -26.45%. Viatris' return on equity of 16.20% beat Metsera's return on equity.Company Net Margins Return on Equity Return on Assets Viatris-26.45% 16.20% 7.01% Metsera N/A N/A N/A Do institutionals & insiders believe in VTRS or MTSR? 79.9% of Viatris shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryMetsera beats Viatris on 7 of the 12 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.09B$2.91B$5.55B$9.04BDividend YieldN/A2.44%5.22%4.00%P/E RatioN/A21.5627.6420.24Price / SalesN/A275.02417.15117.30Price / CashN/A42.7336.8958.10Price / Book-11.977.518.035.67Net Income-$209.13M-$55.14M$3.18B$249.21M7 Day Performance3.01%4.61%2.93%3.28%1 Month Performance7.13%0.90%1.72%3.95%1 Year PerformanceN/A5.40%34.39%20.98% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$29.45+2.0%$55.00+86.8%N/A$3.09BN/A0.0081VTRSViatris2.6598 of 5 stars$9.01-1.2%$10.40+15.4%-10.4%$10.70B$14.74B-2.8432,000QGENQiagen4.0435 of 5 stars$47.76-0.6%$49.40+3.4%+21.0%$10.68B$1.98B119.765,765Dividend AnnouncementMRNAModerna4.3784 of 5 stars$27.16-1.4%$46.61+71.6%-74.2%$10.65B$3.24B-3.115,800Options VolumeASNDAscendis Pharma A/S3.5022 of 5 stars$172.22-0.4%$220.67+28.1%+28.2%$10.57B$393.54M-27.421,017News CoveragePositive NewsAnalyst ForecastBBIOBridgeBio Pharma4.6843 of 5 stars$44.86-0.6%$57.42+28.0%+69.7%$8.57B$221.90M-12.71400News CoverageInsider TradeAnalyst RevisionHigh Trading VolumeBPMCBlueprint Medicines1.5556 of 5 stars$128.110.0%$128.060.0%+14.8%$8.28B$508.82M-51.87640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.6057 of 5 stars$93.82-0.6%$101.10+7.8%+466.0%$8.04B$42.28M-46.9130Positive NewsAnalyst ForecastROIVRoivant Sciences1.5397 of 5 stars$11.39-1.8%$17.50+53.6%+1.8%$7.89B$29.05M-45.56860ELANElanco Animal Health2.4008 of 5 stars$14.32+0.1%$15.17+5.9%+2.9%$7.10B$4.44B19.349,000News CoverageAnalyst ForecastRVMDRevolution Medicines4.5764 of 5 stars$36.91-1.5%$67.58+83.1%-1.4%$6.98B$11.58M-9.23250Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies VTRS Alternatives QGEN Alternatives MRNA Alternatives ASND Alternatives BBIO Alternatives BPMC Alternatives VRNA Alternatives ROIV Alternatives ELAN Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
